Advanced Drug Delivery Market by Drug Delivery System (Nanocarriers, Hydrogel, Transdermal, and Microneedle Patch), End-user (Hospitals, Specialty Clinics, and Others), and Regional Analysis (North America, Europe, Asia-Pacific, and LAMEA): Global Opportunity Analysis and Industry Forecast, 2021–2028

Global Advanced Drug Delivery Market Analysis

The global advanced drug delivery market size is predicted to garner $94,352.5 million in the 2021–2028 timeframe, growing from $45,730.0 million in 2020, at a healthy CAGR of 10.0%.

Market Synopsis

Advancements in drug delivery technology have led to the development of many pharmaceutical formulations that have improved patient health by delivering therapeutic to target site, minimizing off-target accumulation, and facilitating patient compliance. Increasing R&D spending for developing therapeutics for cancer, diabetes, and chronic heart diseases is the main factor driving the growth of the advanced drug delivery market.

High development costs and poor stability are projected to hamper the market growth of the advanced drug delivery market.

According to the regional analysis, the Asia-Pacific advanced drug delivery market is anticipated to grow during the review period and generate revenue of $19,531.0 million in 2028, with a CAGR of 11.0%. The growing healthcare spending is the key factor driving the growth of advanced drug delivery market in the region.

Advanced Drug Delivery Overview

The term advanced drug delivery refers to technologies that control the rate at which drugs are released. This technology can deliver therapeutics to the targeted site. Advanced drug delivery systems have the advantage of delivering drugs more precisely and accurately to specific sites, reducing variability in systemic drug concentrations, and enhancing drug absorption.

Impact Analysis of COVID-19 on the Global Advanced Drug Delivery Market

The highly contagious novel coronavirus has created havoc worldwide. Around 400 million people were infected in 210 countries, triggering colossal economic crises due to the measures taken by the government to contain the spread of the virus. The spread of coronavirus impacted all phases of the drug development process and forced many pharmaceuticals, biotechnology, and research institutes to halt their R&D activities and production. As a result, there was a shortage of life-saving medicines in most affected countries.

Currently, there is no clinically approved medicine to treat COVID-19. As a result, many small life science companies collaborated with pharmaceutical and biotechnology giants to develop therapeutics for the novel coronavirus. Increasing R&D activities can pave opportunities for nanocarrier technology. The nanocarrier technology could lead to a variety of applications, which could be developed into risk-free approaches to successfully immunize against the severe acute respiratory syndrome coronavirus 2 (SARSCoV2), which is the main cause of the disease.

Besides, many life science companies such as AstraZeneca, Pfizer, GSK, Gilead, and Johnson & Johnson, among others are working towards developing effective medicines for cancer, diabetes, heart disease, among others, paving the growth opportunity for the advanced drug delivery market in the coming years.

Increasing Incidence rate of Cancer Is Projected to Drive the Market Growth

Improving healthcare infrastructure, spending, and increased access to advanced diagnosis facilities led to the early diagnosis of life-threatening diseases. Besides, improving living standards has led to a sedentary lifestyle and increased access to high-calorie food products. As a result, the number of people with cancer, heart disease, diabetes, and obesity has increased.

Cancer is the leading cause of death in the world. According to the World Health Organization, cancer accounted for 10 million deaths in 2020. As per the estimates, 33% of deaths from cancer are due to tobacco use, high body mass index, alcohol consumption, low fruit & vegetable intake, and lack of physical activity.

Over the years, nanotechnology has been used in medicines, treatments, diagnosis, and tumor targeting. Nanoparticle-based drug delivery systems have shown many benefits in cancer treatment, such as improved stability and biocompatibility, enhanced permeability & retention effect, precise targeting of tumor cells, reduction of side effects, and drug resistance. The growing application of nanoparticle-based drug delivery systems in cancer treatment will drive the growth of the advanced drug delivery market in the coming years.

To know more about global advanced drug delivery market drivers, get in touch with our analysts here.

Low Penetration and Poor Bioavailability of Nanoparticle-based Drug Delivery to Restrain Market Growth

A nanotechnology-based drug delivery system has aimed to decrease normal tissue toxicity by improving drug specificity to tumors. However, the problem with most nanoparticles is their poor penetration into the body due to heterogeneities in vascular permeability. In addition, slow drug release causes poor bioavailability. These factors are expected to restraint the growth of the advanced drug delivery market.

Increasing R&D Activities to Develop Advanced Drug Delivery Systems to Generate Huge Opportunities

Pharmaceutical and biotechnology companies are developing novel drug delivery technologies for targeted and controlled release of novel molecules in tissues and cells to optimize their potential benefits for patients. As a result, companies have increased R&D activities and spending for developing advanced drug delivery systems.

Companies such as AstraZeneca are working on a wide array of nanoparticles to deliver drugs precisely to the target site and control the release of therapies in formulations that are easy for patients to use. Growing R&D activities to develop novel drug delivery technologies are projected to provide growth opportunities in the coming years.

To know more about global advanced drug delivery market opportunities, get in touch with our analysts here.

Source: Research Dive Analysis

The nanocarriers sub-segment is anticipated to have a dominant market share and generate a revenue of $69,389.3 million by 2028, growing from $32,740.2 million in 2020. The growing use of nanocarriers technology in the treatment of cancer, diabetes, and heart diseases is driving the nanocarriers drug delivery sub-segment. Furthermore, increasing R&D spending and the importance of nanocarriers in precisely delivering drugs at the target site will provide an opportunity for market growth.

Source: Research Dive Analysis

The hospital sub-segment is anticipated to have a dominant market share and generate a revenue of $44,710.0 million by 2028, growing from $21,768.1 million in 2020. The governments of developing countries have increased spending on improving the country's healthcare infrastructure. As a result, the number of hospital beds has increased. Furthermore, the availability of advanced diagnosis instruments has led to an increasing number of patients visiting hospitals for treatment. Such factors are expected to drive the growth of the advanced drug delivery market in the coming years.

The specialty clinics sub-segment is projected to grow with the highest CAGR of 10.2% from 2021 – 2028. The rising incidence of lifestyle diseases and increasing spending power of the middle-class population have led to an increase in the number of specialty clinics. Furthermore, specialty doctors maintain a relationship with patients and are aware of patients' health. Specialty doctors can address the health problem quickly. As a result, the number of specialty clinics in developing countries is increasing at a significant pace. Such factors are projected to drive the sales of the advanced drug delivery market.

Source: Research Dive Analysis

The Market for Advanced Drug Delivery in North America to be the Most Dominant

North America advanced drug delivery market accounted for the highest market share in 2020. The region accounted for $19,938.3 million in 2020 and is estimated to reach $39,722.4 million by 2028, with a CAGR of 9.5%. Novel pharmaceutical & biotech formulations are easily accessible in North America. Improved healthcare infrastructure and the availability of skilled doctors & medical practitioners drive the market growth. The growing prevalence of cancer and heart disease is expected to drive the market growth of the advanced drug delivery market.

Asia-Pacific Advanced Drug Delivery Market is Expected to Grow with the Highest CAGR from 2021 – 2028

Asia-Pacific advanced drug delivery market is projected to grow with a CAGR of 11.0% from 2021 – to 2028. Improving healthcare infrastructure and the growing availability of novel drug delivery systems are the main factors driving the growth of the advanced drug delivery market. Besides, growing medical tourism will further boost the growth of the advanced drug delivery market. Growing patient pool and supportive government initiatives to increase access to better healthcare facilities will provide significant growth opportunities for the advanced drug delivery market.

Competitive Scenario in the Global Advanced Drug Delivery Market

Acquisition and investment are common strategies followed by major market players.

Source: Research Dive Analysis

Some of the leading advanced drug delivery market players are Bausch Health Companies Inc., Novo Nordisk A/S, Ocular Therapeutix, Inc., 3M, Raphas Co., Ltd., GALDERMA, NanoPass, Altaris, Micropoint Technologies., and Takeda Pharmaceutical Company Limited.

Porter’s Five Forces Analysis for the Global Advanced Drug Delivery Market:

• Bargaining Power of Suppliers: The presence of large number of suppliers reduces their profits as the buyer can switch from one supplier to another based on the cost factor and demand.
  Thus, the bargaining power of suppliers is low.
• Bargaining Power of Buyers: There is significant number of suppliers in the market. Buyers can easily switch from one supplier to another.
  Thus, buyer’s bargaining power will be high.
• Threat of New Entrants: Since large investment is required for R&D and product manufacturing, it discourages new entrants.
  Thus, the threat of the new entrants is low.
• Threat of Substitutes: There is high presence of traditional drug delivery system in the global market.
  Thus, the threat of substitutes is moderate.
• Competitive Rivalry in the Market: The presence of equal player and minimal product differentiation increases competition.
  Therefore, competitive rivalry in the market is high.